Functional Identification of Therapeutic Vulnerabilities in mCRPC
We use unbiased, in vivo and genome-wide CRISPR screening approaches to indentify therapeutic vulnerabilities of the most aggressive, currently incurable prostate tumors.
Epigenetic drivers of Prostate Cancer Bone Metastasis
We study how particular epigenetic modifiers can impact prostate cancer development and progression to bone metastasis, as well as how they might influence resistance to standard of care and experimental therapies.
Education
Bachelor's, University of Buenos Aires
PhD, University of Buenos Aires
Postdoctoral training, Columbia University
Honors & Awards
2022
NCI K22 Career Development Award to Promote Diversity
2021
Young Investigator Award, Prostate Cancer Foundation
2018
Dean’s Precision Medicine Research Fellowship, Columbia University
2017
Irving Institute Clinical Trials Office Pilot Award, Columbia University
2015
Postdoctoral Training Award, Department of Defense
2013
René Barón Foundation Award in Medical Sciences, National Academy of Medicine, Argentina
2009
CONICET Predoctoral fellowship, Ministry of Science, Argentina
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Arriaga did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Arriaga did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
